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Abstract
IFN-lambda (IFN-λ) induces an antiviral state in many cell types and may contribute to the overall
inflammatory environment following infection. Either of these effects may influence adaptive
immune responses, but the role of type-3 interferons in the development of primary and memory T
cell responses to infection has not been evaluated. Herein, we examined T cell responses to acute
or persistent lymphocytic choriomeningitis virus (LCMV) infection in IFN-λR1-deficient mice.
Following acute infection, we find that IFN-λR1-deficient mice produced normal levels of
interferon, robust NK cell responses, but greater than normal CD4+ and CD8+ T cell responses
compared to WT Balb/c mice. There were more T cells that were IL-7Rhi and, correspondingly,
the IFN-λR-deficient mice showed a 2–3-fold increase in memory T cell number. The inhibitory
effect of IFN-λR expression was independent of direct cytokine signaling into T cells. In contrast
to acute infection, the IFN-λR-deficient mice generated markedly diminished T cell responses and
had greater weight loss compared to WT mice when confronted with a highly disseminating
variant of LCMV. These data indicate that IFN-λR limits T cell responses and memory following
transient infection but augments T cell responses during persisting infection. Thus, the immune
regulatory functions for IFN-λR are complex and vary with the overall inflammatory environment.
Introduction
Interferons (IFN) play a key role in limiting virus replication and stimulating adaptive
immune responses against virus infections. The IFN-λs (a.k.a.: type-III IFN; IL-28/29) are a
new family of interferons (1–3) that are found in many species, including humans, mice,
bats, chickens, amphibians, and fish (4–7). There are three subtypes of IFN-λ in humans (λ1,
λ2, λ3) and two in mice (λ2 & λ3; λ1 is a pseudogene). IFN-λ is highly conserved in human
populations, implying strong evolutionary selection for these genes for protection against
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infections (8). Genetic polymorphisms in IFN-λ are associated with either enhanced
clearance of HCV or poor outcomes (9–13). While several models demonstrate that IFN-λ
signals reduce virus replication in cell lines or in vivo, the role of type-III interferons in
adaptive immune responses is less well understood.
IFN-λ are induced by many cell types, including pDCs, cDCs, peritoneal macrophages, T
cells, B cells, eosinophils, hepatocytes, neuronal cells, and epithelial cells, after virus
infections or following activation of TLRs-3, -4, -7, -9, stimulation of RIG-I, or Ku70 (9,
14–25). IFN-λs are induced by either IRF3, IRF7, or NFkB pathways (1). The IFN-λs bind
as monomers to the λR1 (IL-28Rα), which then pairs with IL-10Rβ to form the functional
heterodimer receptor (2, 3). λR signals are transmitted through the JAK1/TyK2, STAT1,
STAT2, STAT3, STAT5, and IRF-9 pathways to induce transcription of IFN-stimulated
genes via ISGF3 (1, 26–28). These signals result in the induction of 2′-5′ oligoadenylate
synthetase (OAS), serine/threonine protein kinase (PKR), ISG56, and IFN-λ2/3 (14, 28). By
comparison with IFN-αβR signals, IFN-λR induces longer-lived activated (tyrosine-
phosphorylated) STAT1 and STAT2 and more strongly induces interferon responsive genes
(MX-1, ISG15, TRAIL, SOCS1) (29).
IFN-λ blocks the replication of numerous viruses in vitro, including encephalomyocarditis
virus (14), West Nile virus (30), vaccinia virus (22), vesicular stomatitis virus (31), foot-
and-mouth disease (32), herpes simplex virus 1 (33–35), influenza A virus (36–38), HIV
(39), HCV and HBV (31, 40–43). The importance of this pathway in host defense is
highlighted by the finding that several viruses have independently evolved mechanisms to
block IFN-λ or its function. For example, the NS1 and NS2 proteins of pneumonia virus, a
member of the paramyxoviridae, blocks IFN-λ induction (44). The NS3/4A protease of
HCV blocks IFN-λ production (45). A secreted glycoprotein from Yaba-like disease virus
blocks IFN-λ signals (46). Vaccinia Virus inhibits IFN-λR-mediated signals and gene
expression and blocks the IFN-λR antiviral response through a PKR-dependent pathway
(47); moreover, a recombinant-vaccinia virus that over-expresses IFN-λ shows reduced
levels of replication in vivo, indicating that poxviruses are susceptible to this interferon and
have evolved mechanisms to limit its activity (22). Promising results from clinical trials
indicate that pegylated-IFN-λ treatment diminishes HCV RNA in patients (9, 48).
The receptor for IFN-λ is expressed on DC, macrophages, and epithelial cells in the
gastrointestinal and respiratory tracts, although evidence suggests that other cell types are
responsive to IFN-λ (36, 49, 50). While some evidence indicates that IFN-λR expression on
peripheral leukocytes is not functional (51), other evidence shows clear antiviral innate
defense in some of these cells, and IFN-λ signals stimulate monocytes and macrophages to
produce IL-6, IL-8, and IL-10 (52). These findings suggest that IFN-λ has an important role
in innate immunity as a first-line defense against invading pathogens through skin and
mucosal surfaces but may also function during systemic infections. Mice lacking both
IFNαβR and IFN-λR show increased susceptibility against respiratory viruses compared to
WT, IFNαβR1-KO, or IL28Rα-KO (36, 37). Recombinant IFN-λ given to mice protects
against influenza infection because the IFN-λR is expressed on the epithelial cells targeted
by the virus (37). At intestinal mucosal sites, IFN-λ shows antiviral functions that are
independent of type-1 interferons (50), and IFN-λR-deficient (λR-deficient) mice are more
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susceptible to rotavirus infection than IFN-λR-sufficient mice (50). Thus, the antiviral
activities of IFN-λ largely depend on the type of virus and the route of administration of
recombinant-IFN-λ (36, 37). IFN-λ may exert protective antiviral functions in multiple
tissues. For example, pegylated-IFN-λ treatment improves immunity to chronic HCV (9,
48), which indicates that it can improve immunity in the liver. Together, these data suggest
that IFN-λ may function in immune defense against systemic infections, since numerous
immune cell types respond to IFN-λ, IFN-λ improves T cell-based vaccination (53, 54), and
IFN-λ reduces hepatropic infection (9, 48).
The effect of IFN-λ on adaptive immune responses is unclear since multiple groups working
in different model systems have arrived at varying conclusions. For example, in a macaque
DNA vaccination model, vaccine-induced CTL responses were improved when an
additional IFN-λ-expressing plasmid was included to enhance granzyme-dependent killing
(53). Similarly, an IL-28B-adjuvanted DNA vaccine strongly induced IFNγ+ CD8+ T cells
and long-lasting Th1-phenotype memory CD4+ T cells in macaques (54). However, IFN-λ
may have immunoregulatory functions in addition to the demonstrated antiviral functions.
The IFN-λRβ–chain is shared with several additional cytokine receptors, including IL-10,
IL-19, IL-20, and IL-22, which have well-defined immune-modulatory functions following
infections. Consistent with this, IFN-λ-stimulated DC induced the proliferation of T-reg
cells in vitro (55); although over-expression of IFN-λ in vivo resulted in fewer Treg cells in
a DNA vaccination model (56). IFN-λ signals inhibit the in vitro differentiation of Th2 cells
but stimulate Th1 cells (57, 58). RSV-infected monocyte-derived dendritic cells secrete IFN-
λ that limits the in vitro proliferation of CD4+ T cells (59). Thus, a mixture of in vitro and in
vivo data show that IFN-λ mediated signals can exert positive or negative effects on T cells.
The overall influence of IFN-λ on innate and adaptive immune responses against systemic
virus infections is not understood. Herein, we explored the role of IFN-λ using IFN-λR-
deficient mice (24) that were given either acute LCMV-Armstrong infection or the highly
disseminating variant, LCMV-Clone13. We evaluated the effects of λR-deficiency on
interferon induction, NK cell frequencies, virus-specific B cell responses, and primary &
memory T cell responses. We found that λR-deficient mice efficiently induced type-1
interferons and eliminated acute infection with kinetics indistinguishable from those of WT
mice. Virus-specific memory B cell responses and antibody also appeared normal without
IFN-λ signals. However, λR-deficient mice showed a 3-fold increase in primary & memory
T cell responses compared to WT mice. In contrast, λR-deficient mice were unable to
sustain T cell responses when exposed to persistent virus infection. Thus, IFN-λR signals




BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, Maine) and were used
as controls for the IFN-λR-deficient mice. In some experiments, BALB/cBy.PL-Thy1a/ScrJ
mice from the Jackson Laboratory were used as recipients of BALB/c or IFN-λR-deficient
cells. Mice deficient in IFN-λ receptor-1 (IL28Rα−/−; λR-deficient) on the BALB/c
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background were originally generated by ZYMOGENETICS (Seattle, WA). All animal
experiments were performed in accordance with the Institutional Animal Care and Use
Committee at the University of North Carolina at Chapel Hill. Adult mice (8–10 weeks old)
received an intraperitoneal injection of 2×105 PFU of the Armstrong CA-1371 strain
(LCMV-Arm) of LCMV. Some mice were given an intravenous injection of 2×106 PFU of
LCMV-Armstrong or LCMV-Clone13. Viral stocks of plaque-purified LCMV were
prepared from infected BHK-21 monolayers. The virus titer in various organs was
determined by plaque assay on Vero cell monolayers (60). Some mice were infected with
1×103 colony forming units of recombinant-Listeria monocytogenes (rLM) that expresses
OVA (61, 62).
RT-PCR
A reverse transcriptase reaction was performed to identify viral RNA (63). RNA was
extracted from 5mg of spleen using RNeasy mini kit (Qiagen; www.qiagen.com) and cDNA
was synthesized using SuperScript-II with random primers (Promega Corp.;
www.promega.com). The cDNA was at 37°C for 20minutes followed by a denaturation step
at 98°C for 5 minutes. PCR was performed using NP5-001
(TCCATGAGTGCACAGTGCGGGGTGAT) and NP3-001
(GCATGGGAAAACACAACAATTGATC) primers to amplify the NP region of LCMV S
RNA. The PCR conditions were: 95°C, 15 minutes; [94°C for 30 seconds; 60°C for 90
seconds; 72°C for 90 seconds] × 35 cycles; 72°C for 10 minutes. Ten μl of the PCR product
were run on gel electrophoresis on a 1.5% agarose gel using a 100bp ladder as a size
reference.
Flow cytometry & ICCS
Single-cell leukocyte suspensions were prepared from spleens and erythrocytes were
removed using ACK lysing buffer (Gibco-BRL, Grand Island, NY). Single-cell suspensions
of splenocytes were surface stained with combinations of fluorescently labeled monoclonal
antibodies that were specific for CD4 (clone RM4-5), CD8 (53–6.7), CD44 (IM7), CD62L
(MEL-14), CD19 (6D5), B220 (RA3-6B2), CD11a (M17/4), KLRG1 (2F1/KLRG1), PD1
(10F.9G2), CD127 (A7R34), CD49b (DX5), CD335 (NKp46; 29A1.4), Thy1.2 (30-H12).
The intracellular staining (ICCS) assay was performed as described previously (64, 65). For
intracellular staining for T cells, splenocytes were cultured with or without LCMV or rLM
peptide in the presence of brefeldin A. After 5.5 h of incubation, cells were stained for
surface markers, washed, fixed with formaldehyde, then permeabilized and exposed to
mAbs specific for IFN-γ (XMG1.2), IL-2 (JES6-5H4), TNF (MP6-XT22), or T-bet (4B10).
Spleen cells were stimulated with NP118-126 peptide to quantify virus-specific CD8+ T cells,
or spleen cells were stimulated with one of several peptide epitopes that bind to I-Ad
(GP176-190; NP116-130), I-Ed (NP6-20), or both (Z31-45) to identify cytokine producing CD4+
T cells (66). Listeria p60217-225 or LLO91-99 were used to stimulate CD8+ T cells after rLM
infection (61, 62). Antibody stained cells were detected by a FACSCalibur cytometer (BD
Biosciences) and the data were analyzed with FlowJo software (Tree Star). All listed mAbs
above were purchased from Biolegend, except for CD11a (eBioscience).
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Memory B cell assay
An ELISPOT-based assay to identify LCMV specific memory B cells capable of
differentiating into antibody secreting cells was performed as previously described (67, 68)
with some modifications. Briefly, single-cell suspensions of splenocytes at a final
concentration of 2×106 cells/ml were cultured in 96-well round bottom culture plates for 5.5
days in the presence of protein A from Staphylococcus aureus (Cowan strain bacteria;
Sigma-Aldrich), pokeweed mitogen (Sigma-Aldrich), and CpG oligonucleotide (ODN-2006;
Invitrogen); at the end of the culture, the cells were replica plated onto ELISPOT plates
(MAHA N4510; Millipore) that were coated with virus-infected BHK lysates, uninfected
BHK lysates, or 1μg/well donkey polyclonal anti-mouse IgG (H+L) (Jackson
ImmunoResearch). The ELISPOT plates were counted by a reader (Cellular Technology
Ltd.). We calculated the frequency of antigen specific B cells among total IgG positive
memory B cells.
ELISA
Serum IL-10 was measured using the Quantikine Mouse IL-10 Immunoassay Kit (R&D
Systems Inc., Minneapolis, MN) according to manufactur’s instructions. IFN-α was
quantified by VeriKine Mouse Interferon-Alpha ELISA Kit (PBL, Piscataway, NJ)
according to manufacturer’s instructions. LCMV-specific serum antibody was quantified by
using ELISA plates (Greiner bio-one, Monroe, NC) that were coated with lysates from
LCMV-infected BHK cells as described previously (69).
Statistics
The graphs show mean data ± sem. The statistical significance was determined by Student’s
two-tailed t-test with Prism 5 software (www.graphpad.com). Comparisons were considered
significantly different when P < 0.05.
Results
IFN-λR-deficient mice generate robust interferon, NK cell, and primary T cell responses to
quickly resolve acute LCMV infection
Type-1 interferons are induced early after LCMV infection. Plasmacytoid-DCs are
responsible for production of IFN-α by day 1, and other cell types make lower amounts of
IFN-α later (70). Type-1 interferons directly inhibit virus replication, activate NK cell
responses against infected cells, and stimulate adaptive T cell responses. Given the parallel
relationship between IFN-λ signals and type-1 interferon expression, we considered that
type-1 IFN expression might be perturbed in the λR-deficient mice. However, λR-deficiency
did not impact type-1 IFN levels following virus infection, as the λR-deficient mice
generated normal levels of IFN-α in the serum (Supplemental Fig. 1A).
Type-1 interferons and IFN-λ act on NK cells to increase their antiviral functions (71). To
determine whether IFN-λ affects NK cell responses following infection, cohorts of WT or
λR-deficient mice were given LCMV-Armstrong infection. Before infection, approximately
5% of cells in the blood were NK cells (DX5+NKp46+) in both groups of mice
(Supplemental Fig. 1B). Three days after infection, 10–20% of blood cells were
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DX5+NKp46+ NK cells in both groups of Armstrong-infected mice, indicating that NK cell
frequencies in the blood increased independently of IFN-λ signals. The number of NK cells
in the spleen was similar in both groups of mice at day 3 after infection (Supplemental Fig.
1C).
Interferon-λs induce antiviral activity against a number of viruses, including influenza,
poxvirus, herpesvirus, and HCV (14, 22, 35–37, 47, 50, 72). Early analyses showed that λR-
deficient mice and WT mice replicate similar levels of virus in the spleen 3 days after
LCMV-Arm infection (24), but the analyses did not extend to other tissues or later times to
evaluate whether the mice eventually resolved the infection. Since early virus loads can
influence T cell differentiation processes, we quantified the amount of infection at several
times after infection with LCMV-Armstrong. At day 4, λR-deficient mice replicated virus in
the liver, lung, and kidney to levels comparable to those found in WT mice (Fig. 1A) and
viral RNA could be detected in the spleens of both groups by RT-PCR (Fig. 1B). By day 8,
the λR-deficient mice and the WT mice reduced the infection to levels below detection by
plaque assay, and the RT-PCR analyses showed no evidence of viral RNA at day 8 or later
in the spleens (Fig. 1B). IFN-λs play a key role in limiting mucosal infections (36, 37, 50,
72, 73). We considered that the λR-deficient mice might show impaired immunity to LCMV
when the virus was given through a mucosal route. However, the intranasal delivery of
LCMV resulted in similar levels of infection in the spleen and lung in both groups of mice at
day 4 (Supplemental Fig. 2A); by day 8, both groups of mice showed major reductions in
the viral load, resulting in similar levels of infection. Tissue samples from long-term
immune mice were also analyzed and found to have no infectious virus (data not shown),
indicating that there is no virus recrudescence in these mice. Thus, λR-signaling does not
limit the early burden of virus and is not critical for the rapid resolution of LCMV-
Armstrong when it is given parentally or mucosally.
The resolution of LCMV depends upon the formation of large numbers of CD8+ CTL, so
the viral clearance data above implies that λR signals are not needed to generate functional
CTL. Type-1 and type-2 interferons augment antiviral T cell responses (64, 74–77). These
interferons signal directly on responding T cells to increase their accumulation after acute
infection. There is also evidence that these interferons can act through indirect processes to
support responding T cell responses. Since the signaling pathways between IFNλR and
IFNαβR overlap, we investigated whether IFN-λ signals augment virus-specific T cells by
comparing peak CD8+ T cell responses in WT and λR-deficient mice. The λR-deficient
mice showed normal abundances of resting CD8+ T cells before infection (Supplemental
Fig. 3A & data not shown), which implies that IFN-λ signals are not involved in naïve T cell
development or seeding of peripheral organs. Upon infection, there was a tremendous
increase in the frequency of activated, CD44hi, CD62Llo, and CD11ahi CD8+ T cells in the
spleens of WT and λR-deficient mice (Supplemental Fig. 3A); however, the frequencies of
these cells were higher in the λR-deficient mice compared to the WT mice and corresponded
to ~2-fold greater numbers of CD44hi, CD62Llo, and CD11ahi CD8+ T cells in the λR-
deficient mice (Fig. 2A). The overall cellularity of the spleens after infection was similar in
the two groups before and after infection (Supplemental Fig. 3B), indicating that there was a
selective increase in activated CD8+ T cells in the λR-deficient mice.
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All virus-specific T cells are contained within the emergent CD44hi and CD11ahi
populations of cells (78–80), so the data in Fig. 2A and Supplemental Fig. 3A suggest that
there are more virus-specific CD8+ T cells in the λR-deficient mice. Therefore, intracellular
cytokine staining (ICCS) was used to quantify epitope-specific CD8+ T cells in WT and λR-
deficient mice before and at the peak of the T cell response. There was a vigorous NP118-
specific CD8+ T cell response in the λR-deficient mice that was ~4-fold greater than that
seen in the WT mice (Fig. 2B). Combined with total spleen cells counts, this frequency
corresponded to >10×106 more NP118-specific CD8+ T cells in the λR-deficient mice than
in the λR-sufficient mice (Fig. 2B, bar graph).
Differentiating virus-specific T cells acquire the ability to make large amounts of TNF and
IL-2 as they progress into effector and memory cells. Among NP118-specific CD8+ T cells
in both groups of mice, approximately 60% of IFNγ+ve cells also made TNF (Fig. 2C, left)
and 10–15% of IFNγ+ve cells also made IL-2 (data not shown). There was no significant
difference in the amount of IFNγ, TNF, or IL-2 produced by NP118-specific CD8+ T cells at
a per cell level, as indicated by geometric mean fluorescence intensity (data not shown).
However, the λR-deficient mice generated 3-fold greater numbers of IFNγ+TNF+ and IFNγ
+IL-2+ CD8+ T cells at day 8 compared to λR-sufficient mice (Fig. 2C, right). Thus, λR
signals do not impact the cytokine output of virus-specific CD8+ T cells but restrict T cell
number. In contrast to acute LCMV infection, we observed no difference in the expansion of
Listeria monocytogenes-specific CD8+ T cells in WT and λR-deficient mice (Supplemental
Fig. 3C), and the mice cleared the infection in the liver as determined by colony counts on
BHI agar (data not shown). Thus, the expression of IFN-λR leads to reduced T cell
responses to some acute infections, perhaps correlating with the magnitude of the T cell
expansion, which is far greater after LCMV than Listeria monocytogenes. Therefore, we
focused our analyses on T cell responses induced by LCMV infection.
The increased T cell response in the λR-deficient mice suggests that IFN-λ is suppressive in
WT mice. This effect might be mediated by direct signaling into T cells or could be an
indirect consequence of IFN-λ signaling into other cell types. To determine whether T cells
need to express IFN-λR, splenocytes from WT or λR-deficient mice were adoptively
transferred to separate congenic recipient mice that were subsequently given acute LCMV
infection (Fig. 3A). At day 9 post-infection, the NP118-specific donor cells were identified
by ICCS assay in the recipient mice. The overall number of WT and λR-deficient CD8+ T
cells was similar in the WT recipient mice (Fig. 3B). These data imply that IFN-λ signaling
into other cell types accounts for the difference in the virus-specific T cell number when
comparing WT and λR-deficient mice.
Primary CD4+ T cell responses are increased in λR-deficient mice after acute infection
Earlier studies using in vitro stimulated T cell cultures indicated that IFNλ stimulates Th1
cells and inhibits Th2 cells (57, 58, 81, 82). Therefore, we examined the effects of IFNλ on
CD4+ T cell responses to infection. At day 8 after infection, modest levels of CD4+ T cell
activation were revealed by slight increases in the proportion of CD4+ T cells that were
either CD44hi or CD62Llo (data not shown). Several H-2d-restricted epitopes have been
identified (66), which enables the quantitation of epitope-specific T cells in Balb/c mice
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using ICCS. In WT mice, ~0.25% of CD4+ T cells were specific for GP176 or NP6, 0.4% for
NP116, and 0.13% for Z31 (Fig. 4A). These frequencies corresponded to 3–10×104 epitope-
specific T cells per spleen (Fig. 4B). A similar analysis was performed for the λR-deficient
mice, which showed moderately increased percentages of CD4+ T cells specific for each
peptide. Overall, there was a 2-fold increase in the number of CD4+ T cells specific for
GP176, NP6, NP116, and no difference in responses to Z31 (Fig. 4B). The NP116-130 peptide
contains NP118-126, which efficiently stimulates H-2Ld-restricted CD8+ T cells that are the
likely source of non-CD4+ T cells that made IFNγ+ in the center dot plots. In both groups of
mice, the IFNγ+ CD4+ T cells specific for GP176, NP6, and Z31 also produced IL-2. There
was a >2-fold increase in the number of IFNγ+IL-2+ CD4+ T cells specific for GP176 and
NP6 (Fig. 4C). In total, these data indicate the CD4+ T cell response in WT H-2d mice
matures into small populations capable of making IFNγ and IL-2, but those responses are
only moderately increased in the absence of λR signals.
IFNλR is not required to generate humoral immune responses to acute LCMV
CD4+ T cell responses drive strong antiviral B cell responses after LCMV (69, 83). We
examined whether the greater CD4+ T cell responses in the λR-deficient mice affected the
humoral response after LCMV-Armstrong infection. WT and λR-deficient mice showed
comparable numbers of CD19+ B cells before and several times after infection
(Supplemental Fig. 4A & data not shown). The percentage of cells with phenotypic markers
of GC B-cells (CD19+GL7+) at day 15 was higher in λR-deficient mice versus WT mice
(20±1% versus 15±1%), however, when measured by an in vitro memory B cell assay (67,
68) at day 120, there was no statistically significant difference in memory B cell numbers
between WT and λR-deficient mice (Supplemental Fig. 4B). Thus, the elevated GC-
phenotype B cells seen at day 15 did not result in more LCMV-specific memory B cell
responses. Correspondingly, LCMV-specific serum antibody levels were similar in both
groups of mice at days 14 and 49 (Supplemental Fig. 4C). These data indicate that λR-
signals are not involved in differentiating memory B cell or plasma cells following acute
infection.
λR-deficient mice sustain elevated numbers of LCMV-specific memory CD8+ T-cells
The above data (Fig. 2 & 4) show that IFN-λR-deficiency leads to an increase in virus-
specific CD8+ and CD4+ T cells. For CD8+ T cells, IFNs influence the formation of short-
lived effector cells (SLEC) and long-lived, memory precursor cells (MPEC) (84). We
explored whether λR signals affect the development of SLECs (KLRG1hiIL-7Rlo) or
MPECs (KLRG1loIL-7Rhi). Among activated CD11a+ T cells, the λR-deficient mice
showed normal frequencies of SLEC but 2-fold higher frequencies of MPEC at day 8
(Supplemental Fig. 3D), which corresponded to a 1.7-fold increase in SLEC number and a
4-fold increase in MPEC number (Supplemental Fig. 3D). These data suggest that the
expression of IFN-λR restricts the accumulation of cells with memory potential, which
implies there could be long-term effects on T cell memory. Therefore, cohorts of mice were
infected with LCMV-Armstrong, and the virus-specific CD8+ T cell number was quantified
at various times after infection. The λR-deficient mice continued to have 2–3-fold greater
numbers of NP118-specific CD8+ T cells after the peak response (Fig. 5A, top). The
proportions of memory T cells capable of making IFNγ with TNF (Fig. 5A, middle) or IFNγ
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with IL-2 (Fig. 5A, bottom) were also increased in λR-deficient mice compared to WT mice.
At day 180, the λR-deficient mice continued to have nearly 3-fold more NP118-specific
CD8+ T cells and more CD8+CD11a+ T cells that expressed the IL-7Rhi MPEC phenotype
(Fig. 5B) that is associated with memory.
There is no information about the number and epitope-specificity of memory LCMV-
reactive CD4+ T cells in Balb/c mice. Here, we followed CD4+ T cell memory responses in
WT (Balb/c) and λR-deficient mice. Virus-specific memory IFNγ+ CD4+ T cells were
quantified by ICCS at late times after infection. At day 180, the NP116-specific CD4+ T
cells were the largest population of epitope-specific T cells in the WT mice; that population
was 2-fold greater in the λR-deficient mice (Fig. 5C). Approximately 104 CD4+ T cells per
spleen were specific for GP176, NP6, and Z31 in both groups of mice. Among the NP116-
reactive CD4+ T cells, a higher percentage made IL-2 in the λR-deficient mice compared to
the WT mice (Fig. 5D). These data indicate that IFN-λR signals limit the abundance and
cytokine content of immune-dominant memory CD4+ and CD8+ T cells.
IL-2 signals are involved in both the establishment of memory and in the recall response
(85–89). CD8+ T cells in λR-deficient mice made slightly more IL-2 per cell than did CD8+
T cells from WT mice at days 40, 120, and 180 after infection (data not shown). The effect
was small but significant based on an unpaired Student’s t-test P-value of 0.01–0.03 at each
time, with 3–5 mice per group. A similar pattern was observed for CD4+ T cells (Fig. 5D).
This suggests that λR-deficient cells are qualitatively improved compared to cells in WT
mice. Therefore, cohorts of WT and λR-deficient mice were immunized and 4 months later
some were re-challenged with a higher dose of LCMV-Armstrong. As expected, WT mice
mounted a robust recall response by 6 days, with ~6% of CD8+ T cells specific for NP118
and able to make IFNγ (Fig. 5E); the λR-deficient mice generated 2-fold higher frequencies
of these cells, and the same pattern was apparent when TNF and IL-2 production were
quantified (Fig. 5E). These percentages corresponded to 5–10×106 more NP118-specific
cytokine-producing CD8+ T cells per spleen in the re-challenged λR-deficient mice
compared to the WT mice. The larger response in the λR-deficient mice upon re-challenge
corresponded to the greater number of memory cells in these mice before challenge. Thus,
there was no significant increase (Student’s t-test P-value = 0.07) for the λR-deficient mice
compared to the WT mice when the ratio of effector cells after challenge was normalized to
the number of memory cells before challenge. These data indicate that while IFN-λR-
deficient mice establish more memory cells than WT mice, those memory cells are not
inherently better at proliferative responses compared to memory cells in WT mice.
The re-call response in both groups of immune mice led to efficient control of the infection
(Fig. 5F, triangles). By comparison, both groups of naïve mice given the challenge dose
continued to show high levels of infection at day 6 (Fig 5F, circles). Cumulatively, these
data show that λR-dependent signals are dispensable for generating protective primary and
memory T cell and B cell responses after acute infection and act to restrict the size of the
overall response.
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Exaggerated loss of virus-specific T cells during disseminated virus infection
The data above indicate λR signals are dispensable for primary and memory T cell
formation and protection against LCMV-Armstrong infection. The immunobiology of
persisting virus infection is often very different from acute infection, and is largely impacted
by the detrimental effects of sustained T cell stimulation, inhibitory molecule expression on
T cells, and the presence of immune suppressive cytokines. Consequently, T cells undergo
exaggerated deletion or functional inactivation during these conditions. T cell exhaustion is
observed in mice with persisting LCMV infection and in people who are persistently
infected with HIV or HCV. To better understand the role of IFN-λ signals on the resolution
of chronic virus infection, WT and λR-deficient mice were given LCMV-Clone13, which
disseminates and persists. Both groups of mice showed an initial weight loss followed by
partial recovery, although the λR-deficient mice endured greater weight loss than WT mice
(Fig. 6A). Both groups of mice showed similar levels of virus across time (Figure 6B). At
days 9 to 20, there was 105 PFU/ml in the serum and >107 PFU/gram in the liver, lung, and
kidneys in both groups. By day 40, there was a reduction in viremia and eventually both
groups reduced the virus burden to the limits of detection, likely through a combination of T
cell and neutralizing antibody-mediated mechanisms. Thus, there is no apparent effect of λR
expression on peak viral titers or the longevity of the infection.
Compared to the WT mice, there was a significantly greater drop in the total spleen size in
the λR-deficient mice by 8 days after infection (Fig. 6C). The overall cellularity continued to
decline across time to 6×106 cells by day 40 in the λR-deficient mice, whereas the WT mice
had ~3-fold more splenocytes. Virus-specific T cell responses were analyzed by ICCS assay
at days 8, 40, and 90 after LCMV-Clone13 infection. At day 8, the overall abundance of
IFNγ+ CD8+ T cells and CD4+ T cells was similar for the two groups (data not shown). In
the λR-deficient mice, a smaller percentage of activated CD8+ T cells were KLRG1hi, fewer
expressed the inhibitory molecule PD-1, and more were CD127hi (data not shown), which
suggested that more T cells might survive to contribute to immune control in the λR-
deficient mice. However, by day 40, there were 4-fold fewer virus-specific NP118-specific
CD8+ T cells (Fig. 6D) and 3-fold fewer GP176-specific or NP6-specific CD4+ T cells (Fig.
6E) in the λR-deficient mice compared to the WT mice. The reduced T cell responses were
near or below the limits of detection, and this pattern was sustained to day 90 (data not
shown). Much of this reduction in virus-specific T cell number was due to the lower number
of spleen cells in the λR-deficient mice (Fig. 6C). In contrast to Clone13, LCMV-Armstrong
led to 2–3-fold greater numbers of virus-specific CD8+ and CD4+ T cells in the λR-
deficient mice compared to WT mice (Fig. 6D–E). These data show that IFN-λ functions
vary with the chronicity of the infection. During persisting infection, IFN-λ signals protect
against infection-induced weight loss and sustain IFNγ+ T cell responses. Following acute
infection, IFN-λ limits the size of the overall T cell response and memory.
Discussion
Earlier analyses of IFN-λ focused on its role in limiting virus infection or replication, but
much less is known in terms of how this pathway influences adaptive immunity. Herein, we
examined primary and memory T cell responses after acute and persisting virus infection in
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λR-deficient mice. We found IFN-λR is not essential for mounting innate and adaptive
antiviral defense and appears to regulate peak effector T cell responses and memory cell
number after acute infection. In contrast, T cell responses to disseminating infection were
reduced in the λR-deficient mice, implying that IFN-λ signals maintain T cell responses
during persisting infection. The λR-deficient mice also showed greater weight loss that was
prolonged compared to WT mice.
While the main effect of λR-deficiency was on T cells, we observed a modest trend toward
increased NK cell frequencies in the blood after infection in the λR-deficient mice
(Supplemental Fig. 1B &1C). The increase achieved significance after Clone13 infection but
not after Armstrong infection. NK cells are induced by type-1 and type-2 interferons, so the
increased NK cell response in the λR-deficient mice suggests that IFN-λ signals may
counterbalance the inducing effects of these other interferons. Other investigators have
shown that the antitumor activity of IFN-λ is partly mediated by positive effects on NK cell
recruitment into the liver and increased tumor killing by NK cells (71). IFN-λ is being tested
in clinical trials to treat HCV infection (9, 48, 90); in addition to directly limiting HCV
replication in liver cells, IFN-λ may stimulate antiviral activity in hepatic NK cells to reduce
HCV. NK cells restrain virus-specific T cell responses following LCMV-Clone13 infection
and contribute to the formation of functionally exhausted T cells (91–94). Thus, the
increased NK cell response in the Clone13-infected IFN-λR-deficient mice might contribute
to greater NK cell activity and the eventual decline in virus-specific T cell responses during
the chronic stage.
The levels of infectious virus early after LCMV-Armstrong infection were comparable in
λR-deficient mice and WT mice (Fig. 1A, Supplemental Fig. 2), consistent with an earlier
report (24), and another study showing that pre-treating mice with 10μg of recombinant-
IFN-λ does not reduce LCMV levels at day 2 after infection (14). This implies that λR-
deficient mice do not have new cellular targets of infection. IFN-λR signals do not limit the
replication of the arenavirus, Lassa virus, in macrophages or DCs in vitro (95) and mice
lacking IFN-λR did not show increased levels of Lassa virus replication compared to mice
with the IFN-λR following intranasal infection (36). IFN-λR is important for the resolution
of other infections at mucosal or liver sites; however, our analyses showed no difference in
the lung or liver, when LCMV-Armstrong was given intranasally (Supplemental Fig. 2).
LCMV causes a systemic infection that induces robust levels of IFNαβ and IFNγ. In this
context, direct IFNαβR and IFNγR signals may induce sufficient antiviral activity to impair
early virus replication, thus overshadowing any antiviral effects mediated by IFN-λ (24).
We found that the overall CD8+ T cell response to acute infection was increased in the
absence of IFN-λR signals. There are several potential explanations for our findings. 1)
pDCs express IFN-λR and are a primary source of IFNαβ immediately after LCMV
infection. It is plausible that pDCs (55, 96) or a monocyte-derived lineage (52) were less
active in the λR-deficient mice, leading to slightly higher antigen loads that stimulate T
cells. Such slight differences in antigen-load would not be revealed by the plaque assay or
RT-PCR analysis but may be sufficient to induce more T cell accumulation. 2) IFN-λ may
affect T-reg activity. IFN-λ are increased during the chronic stage of HCV and act on DC to
stimulate CD4+FoxP3+ T-reg cells (55, 97), perhaps suppressing immune responses to
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HCV. A novel population of CD4+FoxP3+CD25− T cells make IFN-λ and induce tolerance
in a mouse EAE model (98), so potentially these tolerance-inducing populations of cells are
induced in the infected WT mice but are diminished in the λR-deficient mice. 3) Finally, it
has been shown that IFN-λ signals can induce SOCS1 and SOCS3 (99) that suppress
inflammatory processes. All of these potential mechanisms are likely to be indirect as it does
not appear that IFN-λ signals act directly on T cells. In some models activated T cells
express λR (58, 100, 101), however, we could not detect IFN-λR expression on naïve or
activated T cells using flow cytometry, and mRNA levels for IFN-λR appeared to be very
low based on RT-PCR (data not shown), consistent with other findings for human T cells
(102). Moreover, λR-deficient T cells did not respond better than WT T cells when the cells
were placed in acutely infected WT mice (Fig. 3). Thus, the effects we observe on antiviral
T cell number likely occurred as a result of IFN-λ signaling in other cell types.
Interestingly, the expression of IFN-λR was associated with sustained T cell responses
during persisting infection, which contrasts with the restraining effects of IFN-λ on T cells
during acute infection. We do not know why antiviral T cell responses collapsed in the
chronically infected λR-deficient mice, nor do we know why the effects of IFN-λ are
opposite following acute and chronic infection. The effects of cytokines on T cell responses
can differ between acute and chronic infections. For example, IL-10 and type-1 IFN also can
stimulate or inhibit T cell responses to LCMV, depending on the duration of the infection.
IL-10 signals during acute LCMV infection increase the formation of MPECs and long-term
memory cells (103) yet limit T cell responses during persisting infection (104–108). Because
IL-10 has been implicated in restricting T cell responses following LCMV infection (104,
107–109), we considered that IFN-λR1-deficiency might impact the amount of IL-10 that is
present in the infected mice. Serum IL-10 levels rapidly rose on day 1 and declined in both
WT and λR-deficient mice after Armstrong or Clone13 infection (Supplemental Fig. 1D).
An interesting rebound of serum IL-10 levels on day 15 post LCMV-Clone13 infection was
observed, consistent with an earlier report (104), but there was no significant difference in
serum levels of IL-10 in the WT or λR-deficient mice at any time during LCMV-Clone13
infection. Type-1 IFNs contribute to the vigorous T cell responses after acute infection but
diminish T cell responses during the chronic stage of LCMV-Clone13 infection (110–112)
and can induce lymphopenia after virus infections (113, 114). We observed that the
Clone13-infected λR-deficient mice had somewhat smaller spleens than WT mice (Fig. 6C),
and we considered that IFN-λ might affect type-1 IFN levels but found that serum levels of
IFN-α were similar between WT and λR-deficient mice (Supplemental Fig. 1).
An alternative hypothesis is that IFN-λ inhibits T cell responses to both acute and chronic
infections, but the differential effects observed on T cell number after LCMV-Armstrong
and LCMV-Clone-13 (Fig. 5) are linked to the tropism of these strains. Thus, LCMV-
Clone13 more efficiently infects fibroblastic reticular cells (FRC) (115, 116) and dendritic
cells and their progenitors (117, 118). Once these cells are infected, they become targets for
CTL and are destroyed, leading to generalized immune suppression and sustained T cell loss
during chronic infection (115–118). FRCs provide factors that support the retention and
expansion of T cell responses to acute infection. However, LCMV-clone13 infection of
FRCs, leads to the disintegration of this important stromal cell network and a subsequent
loss of cell populations (115, 116). Thus, a greater CTL response early on in the Clone13-
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infected λR-deficient mice may explain the exaggerated loss of spleen cell number in these
mice (Fig. 6C). Alternatively, it may be that IFN-λ acts on FRC to protect them from
destruction by CTL in the WT mice. Analogous effects could occur for dendritic cells:
LCMV-Armstrong efficiently activates DCs to stimulate T cells and IFN-λ restrains T cell
responses. In contrast, LCMV-Clone13 targets DCs and leads to their rapid destruction by
CTL (117, 118), and IFN-λ acts to limit CTL-mediated destruction of these DCs. Thus in the
presence of IFN-λ, there could be lengthier DC-driven T cell responses during chronic
infection. Finally, it is possible that IFN-λ supports T cell responses during chronic infection
by limiting Clone13 infection of FRC or DCs without significantly changing the overall
viral burden in the spleen.
Overall, our data indicate that IFN-λ improves T cell responses during chronic LCMV
infection. Recent data from clinical trials show that recombinant-IFN-λ enhances protection
against HCV (48). While IFN-λ synergizes with IFN-β to reduce viral genomes in infected
hepatocytes, our data in Figure 6 suggest an alternative hypothesis: recombinant-IFN-λ
improves antiviral T cell number or function during persisting infection to reduce virus
levels.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. IFN-λR-deficient mice resolve LCMV-Armstrong infection
WT and IFN-λR-deficient (KO) mice were infected intraperitoneally with 2 × 105 PFU of
LCMV-Arm. (A) The level of virus in the indicated tissues was determined by plaque assay
at days 4 & 8 after infection; each symbol represents tissue from an individual mouse
(circles depict measurements at day 4; triangles depict measurements at day 8), the small
horizontal lines indicate the mean titers, the dotted line indicates the limit of detection. The
data represent 3 experiments with 5–6 mice/group; a Student’s t-test indicated no significant
difference in titer between WT and λR-KO mice. (B) The agarose gel shows the product of a
representative RT-PCR reaction utilizing RNA extracted from the spleens of infected mice
and DNA primers complimentary to LCMV-NP. The product of 590 base pairs was found in
day 4 samples but not at day 8 or day 12. The product from day 4-infected IFNαβR−/
−IFNγR−/− (DKO) mice that have very high levels of infectious virus is shown for
comparison.
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Figure 2. Greater accumulation of virus-specific CD8+ T cells in IFN-λR-deficient mice
Groups of WT and λR-deficient (KO) mice were infected with LCMV-Arm. (A) At day 8
after infection, spleen cells were analyzed for CD8, CD44, CD62L, and CD11a by flow
cytometry. The bar graphs show cumulative data for the total number of activated CD8+ T
cells that were CD44hi (left), CD62Llo (middle), CD11ahi (right) in WT and λR-deficient
mice (means ± sem). The data represent 2–5 experiments with 5–11 mice/group at each time
point. (B) NP118-specific CD8 T cell responses in the spleen were quantified by ICCS
followed by flow cytometry analysis. The dot plots show examples of CD8+ T cell
production of IFNγ in response to NP118 peptide on days 0 (uninfected) and 8 after
infection; the numbers indicate the percentage of spleen cells in each quadrant. The bar
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graph shows cumulative data for the number of NP118-specific CD8+ T cells per spleen
from 11–13 mice analyzed in 4 independent experiments (mean ± sem). (C) The
representative dot plots are gated on CD8+ T cells and show the percentage of cells that co-
expressed IFN-γ with TNF, as assessed by ICCS. The bar graphs show cumulative data from
11–13 mice. The left graph shows the average (± sem) number of NP118-specific CD8+ T
cells per spleen that were TNF+IFNγ+; the right graph shows the number that were
IL-2+IFNγ+. The data represent 2–5 experiments with 5–11 mice/group at each time point.
A two-tailed Student’s t-test was used to evaluate significance with **P <0.01; ***P <0.001.
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Figure 3. IFN-λ does not directly act on virus-specific T cells
Cell transfer experiments were performed to evaluate whether IFNλ directly acts on T cells
to affect their expansion after infection. (A) Single-cell suspensions of spleen cells
containing 3.8×106 polyclonal CD8+ Thy1.2+ T cell populations from WT or λR-deficient
mice were transferred intravenously into separate congenic Thy1.1+ mice. The recipient
mice were infected with LCMV-Arm the next day and analyzed by ICCS at day 9. (B) The
top dot plots show surface staining for Thy1.2 and CD8 at day 9. The ovals identify the
donor cells. The bottom dot plots are gated on the donor cells and show their expression of
IFNγ+ following stimulation with NP118 peptide. The graph shows the total number of IFNγ
+ NP118-specific CD8+ T cells per spleen. The data represent 4 mice/group for each
analysis. Based on two-tailed Student’s t-test, there was no significant difference in the
expansion of WT and λR-deficient CD8+ T cells in the WT mice.
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Figure 4. Improved expansion of LCMV-specific CD4+ T cells in the absence of IFN-λR
interactions
Epitope-specific CD4 T cell responses were measured by ICCS assay using spleen cells
from WT (Balb/c) and IFNλR-KO mice 8 days after infection. (A) The representative dot
plots show IFNγ production by CD4+ T cells in response to the indicated LCMV peptides;
the numbers indicate the percentage of cells in each quadrant. (B) The bar graphs show the
average (± sem) number of IFN-γ+ epitope-specific CD4+ T cells per spleen in WT and
IFN-λR-KO mice. (C) The bar graphs show the average (± sem) number of IL-2+ epitope-
specific CD4+ T cells per spleen in WT and IFN-λR-KO. Data are representative of 2
experiments with 7 mice/group. A two-tailed Student’s t-test was used to evaluate
significance with **P <0.01 and ***P <0.001.
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Figure 5. T cell memory is increased in IFN-λR-deficient mice
NP118-specific CD8+ T cells were quantified by ICCS at multiple times after acute
infection. (A) The line graphs show the average (± sem) number of CD8+ T cells per spleen
that made IFNγ (top), IFNγ with TNF (middle), or IFNγ with IL-2 (bottom) at the indicated
days after infection. 3–13 mice per group were analyzed at each time point. (B) The bar
graph shown the number of CD8+CD11hiKLRG1loIL-7Rhi memory T cells in the spleens of
3–4 mice at 180 days after infection. (C) The bar graphs show cumulative data for the
number of CD4+ T cells specific for the indicated MHCII-restricted LCMV epitopes as
measured by IFNγ ICCS assay at day 180. (D) An example of ICCS co-staining for IFNγ
Misumi and Whitmire Page 26






















and IL-2 at day180. Note the greater frequency of cytokine+ve cells in the IFN-λR-KO mice
than in the immune WT mice. (E–F) WT and IFNλR-KO mice were infected
intraperitoneally with 2 × 105 PFU of LCMV-Arm and, 120 days later, were rechallenged
intravenously with 2 × 106 PFU of LCMV-Arm. Six days after the re-challenge, virus-
specific T cell responses in the spleen and viral loads were quantified. (E) The bar graphs
show the number of NP118-specific CD8+ T cells per spleen before (not striped) and after
(striped) the re-challenge. The bar graphs summarize the mean (± sem) of 5 mice per group
and 2 independent experiments and depict the total number of IFNγ+ve cells, IFNγ+TNF+
cells, and IFNγ+IL-2+ cells per spleen. (F) The amount of infectious virus in the liver and
kidney was measured by plaque assay. The inverted triangles show the levels in re-
challenged immune mice; the circles indicate levels found in naïve mice that were given the
re-challenge dose and analyzed 6-days later. The data represent 2 experiments with 4–5
mice/group. A two-tailed Student’s t-test was used to evaluate significance with *P <0.05;
**P <0.01; ***P <0.001.
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Figure 6. IFN-λR-deficient mice fail to sustain virus-specific T cells during persisting virus
infection
WT and IFN-λR-KO mice were infected intravenously with 2×106 PFU of LCMV-
Armstrong or LCMV-Clone13. (A) Weight loss was measured across time during LCMV-
Clone13 infection (mean±sem with n=6–7 mice per group per day). (B) The average (± sem)
viral burden in the serum or indicated tissues was measured by plaque assay at the indicated
days after Clone13 infection. The dotted line indicates the limit of detection of the plaque
assay. 3–7 mice per group were analyzed at each time point. No significant difference was
detected between WT and λR-KO mice using two-tailed Student’s t-test. (C) The line graph
shows the total number of splenocytes (average ± sem) at the indicated days after infection.
6–11 mice per group were analyzed at each time point. A two-tailed Student’s t-test was
used to evaluate significance with **P <0.01 or ***P <0.001. (D–E) Virus-specific T cells
in the spleens of infected WT or KO were analyzed at day 40 by ICCS. (D) The dot plots
show examples of CD8+ T cell production of IFNγ in response to NP118-126 peptide; the
numbers indicate the percentage of cells in each quadrant. (E) The left bar graphs show
cumulative data for the number (mean ± sem) of NP118-specific CD8+ T cells per spleen.
The right bar graphs show the average (± sem) number of IFN-γ-producing GP176 or NP6-
specific CD4+ T cells per spleen. The data represent 2 experiments with 3 mice/group (Arm)
or 7 mice/group (CL13). Asterisks indicate statistical significance (*p < 0.05, **p < 0.01,
and ***p < 0.001) by a two-tailed Student’s t-test.
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